Results
1 -
10 of
29Oral Agents, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease Oral Platelet Glycoprotein IIb/IIIa Blockade, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial, Journal of Thrombosis and Thrombolysis Role of Oral Blockade of Platelet Glycoprotein IIb/IIIa on Neutrophil Activation in Patients with Acute Coronary Syndromes, Cardiovascular Drugs and Therapy Platelet Glycoprotein Ib?? Receptor Polymorphisms and Recurrent Ischaemic Events in Acute Coronary Syndrome Patients, Journal of Thrombosis and Thrombolysis Antiplatelet Therapy in Acute Coronary Syndromes without Persistent ST-Segment Elevation, Cardiovascular Drugs and Therapy Oral platelet glycoprotein IIb/IIIa inhibition, Current Cardiology Reports Oral glycoprotein IIb/IIIa antagonists in coronary artery disease, Current Cardiology Reports Antithrombotic therapy in cardiac stent patients, Current Cardiology Reports Orbofiban in unstable angina (OPUS-TIMI 16 trial), Current Controlled Trials in Cardiovascular Medicine